Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Basf Aktiengesellschaft

Egis Gyogyszergyar Rt.

Egis Cyogyszergvar

Gyula Sebestyen

Sandor Virag

Istvan Hermecz

Agnes Horvath

Zoltan Meszaros

Agoston David

Attila Mandi

Tamas Szuts

Tibor Breining

Gabor Kovacs

Lelle V Vasvari Nee Debreczy

Gabor Nagy

Marta Kovacs

Jozsef Knoll

Marton Fekete

Antal Simay

Dezso Korbonits

Kalman Takacs

Istvan Stadler

Frigyes Gorgenyi

Katalin Marmarosi

Gabor Kulcsar

Janos Egri

Istvan Bitter

Istvan Simonyi

Pal Vago

Ilona K Ajzert

Tibor Zilahi

Marian E Puskas

Maria H Papp

Zoltan Sumeghy

Istvan Seres

Maria Szeli

Gizella Miholics

Tamas Szucs

Csaba Szantay

Lajos Szabo

Kalman Harsanyi

Pal Kiss

Gergely Heja

Endre Palosi

Lajos Szente

Istvan Tibor Toth

Ida Szvoboda Nee Kanzel

Lelle Vasvari

Gyula Papp

Csaba Gonczi

Laszlo Szekeres

Maria Szomor Nee Wundele

Jozsef Kokosi

Jozsef Lengyel

Gyorgy Szasz

Karoly Lapis

Judit Kun

Peter L Nagy

Rudolf Szebeni

Peter Literati Nagy

Erzsebet Kanyo

Josef Szejtli

Emil Minker

Margit Nagy Nee Kricsfalussy

Janos Feher

Katalin Kalloy

Lelle Vasvari, Nee Debreczy

Anna Z Szabo

Rita Balazs

Maria Hornyak

Jozsef Schawartz

Antal Mosonyi

Gizelle Miholics

Egri Janos

Joszef Gaal

Marta Kovcas

Maria Szeli Nee Seger

Maria Hoor

Molnar Leventene

Lelle Vasvari Nee Debreczi

Istvan Bitteer

A pharmaceutical ointment is disclosed containing to 10 percent by mass of micronized piroxicam, 15 to 30 percent by mass of hydrophobic carrier(s), 60 to 75 percent by mass of water, 0.1 to 10 percent by mass of additive(s), and 2 to 5 percent by mass of emulsifiers selected from (i) a poly(ethylene glycol) alkyl or alkenyl ether and (ii) a sorbitane ester of a fatty acid or an oleic acid in a mass ratio of 3:1 to 1:3. The ointment is free from skin irritative action and has local antiphlogistic activity. In addition, a process for preparing he pharmaceutical ointment is provided.

Pharmaceutical ointment being free from skin irritative action and a

The invention relates to a stabile, aqueous suspoemulsion containing as active ingredient 0.2-5 weight % of primycin, 5-25 weight % of propylene glycol, 0.5-5 weight % of non-ionic surface active agent, if desired 15 weight % of auxiliary agent and distilled water in an amount necessary to 100 weight %, as well as to a process for the preparation thereof.

Pharmaceutical composition and process for the preparation thereof

The invention refers to a novel pharmaceutical composition having especially antimycotic activity and comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) ##STR1## and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails. The complex of formula (I) is prepared by reacting a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline with a solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a lower stability constant than that of the complex of formula (I) and separating the product precipitated.

Pharmaceutical composition comprising an organic zinc complex and a

The present invention relates to synergistic pharmaceutical compositions for the treatment of liver disorders comprising 5-aminoimidazole-4-carboxamide orthophosphate (AICA-phosphate) as active ingredient in association with vitamins, preferably with vitamin B and/or E and optionally with other pharmaceutical excipients.

Synergistic pharmaceutical compositions

Antitussive compounds of the formula I ##STR1## or physiologically acceptable acid addition salts thereof are disclosed, where A stands for straight or branched chain C.sub.1-5 alkylene or ##STR2## R.sub.1 stands for straight or branched chain C.sub.1-10 alkyl, halogenoalkyl, hydroxyalkyl, C.sub.5-6 cycloalkyl, vinyl, 2-ethoxyethyl, carbonylalkyl or aminoalkyl of the formula ##STR3## wherein R stands for hydrogen or methyl, n is 0 to 3,

Theophyllinyl-alkyl-oxadiazoles, process for the preparation thereof and

This invention relates to new synergistic antimicrobial compositions containing primycin, doxycycline and sisomicin.

Synergistic antimicrobial compositions

New Rutecarpine analogs are disclosed having Rutecarpine-like activity, especially diuretic activity. Also a novel process for the preparation of the Rutecarpine analogs is disclosed.

Indolo[2',3';3,4]pyrido[2,1-b]quinazoline-5-ones, a process for the

Compounds of the formula I ##STR1## or pharmaceutically acceptable salts, hydrates, stereoisomers, optically active isomers, geometrical isomers or tautomeric forms thereof are disclosed wherein

Nitrogen bridgehead compounds having anti-allergic effect

The invention concerns new sulfur-containing isoquinoline derivatives. More particularly, the invention relates to isoquinoline derivatives of the general formula (I) ##STR1## wherein R independently represents hydrogen, hydroxyl or alkoxy having 1 to 4 carbon atoms,

Sulfur-containing isoquinoline derivatives in pharmaceutical

A synergistic antimicrobial active ingredient for a pharmaceutical or veterinary composition comprises 5 to 50 percent by weight of a primycin component which consists of a primycin fermentation product of Thermonospora galeriensis and 95 to 50 percent by weight of at least one other component selected from the group which consists of doxycyline compounds and sisomicin compounds. The doxycycline compounds are selected from the group which consists of doxycycline, salts thereof with mineral acids, and doxycycline tryclate. The sisomicin compounds are selected from the group which consists of sisomicin, substituted sisomicins with substitution at the N atom by lower alkyl, hydroxyl lower alkyl, lower aminoalkyl and lower alkanoyl, and sisomicin acid salts.

Isoquinolines are disclosed of the formula (I) ##STR1## wherein R independently represents hydrogen, hydroxyl or alkoxy having 1 to 4 carbon atoms,

Sulfur-containing isoquinoline derivatives, process for the preparation

Antiallergic and antiasthmatic compounds of the formula ##STR1## of which 9-phenylamino-6-methyl-4-oxo-6,7-dihydro-4H-pyrido(1,2-a)pyrimidine-3-carb oxylic acid and optically active antipodes and salts thereof are examples.

Antiallergic nitrogen bridge-head compounds

An optically active or racemic fused pyrimidine derivative of the formula I ##STR1## has pharmaceutical activity in decreasing serum lipids, cholesterol deposits and, in general, against atherosclerosis.

Fused pyrimidine derivatives and antiatherosclerotic methods of

Antiallergic and particularly antiasthmatic compounds of the formula: ##STR1## of which 9-phenylhydrazono-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido(1,2-a)pyrimi dine-3-carboxylic acid is an especially significant example.

Growing community of inventors

Budapest, Hungary

Gyula Sebestyen